An open-label study to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world cli

Project: Research project

Project Details

StatusActive
Effective start/end date2/4/25 → 2/3/30

Funding

  • Calliditas Therapeutics AB ( Award # ): $16,900.00